NASDAQ · HSCS
HeartSciences Inc.
$3.61+$0.24 (+7.12%)
HeartSciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.2% below the high.
Loading market information…
NASDAQ · INBS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Intelligent Bio Solutions Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.65% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Intelligent Bio Solutions Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$1.31. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Intelligent Bio Solutions Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:01 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2025 | May 14, 2025 | -$4.40-57.14% vs estimate | $728.87K-77.91% vs estimate |
|---|
| Q2 2025 | Feb 14, 2025 | -$5.00-56.25% vs estimate | $607.49K-73.59% vs estimate |
|---|
| Q1 2025 | Nov 13, 2024 | -$0.70-32.08% vs estimate | $872.29K-51.54% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.61+$0.24 (+7.12%)
HeartSciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.2% below the high.
$1.97-$0.11 (-5.29%)
PAVmed Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.07% below the high.
$3.59+$0.03 (+0.84%)
Mainz Biomed B.V.’s quoted price sits in the upper half of its reported 52-week range, 32.77% below the high.
$1.20-$0.01 (-0.41%)
Bionano Genomics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.19% below the high.
$5.05+$1.34 (+36.12%)
Adial Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.41% below the high.
$1.86+$0.03 (+1.64%)
Check-Cap Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.58% below the high.
$0.91+$0.11 (+13.78%)
Brainstorm Cell Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.15% below the high.
$4.91+$0.29 (+6.28%)
Predictive Oncology Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.3% below the high.
